Figure 3

Overall patient survival in different subgroups. Patient survival illustrated for different EGR1 and EGR3 subgroups in glioblastoma patients both measured by positive cell fractions found in the immunostainings and by mRNA expression data from TCGA. All groups were dichotomized at the median. (A) GBM patients with a high EGR1 nuclear fraction showed a significantly better prognosis compared to patients with a low EGR1 fraction. (B) EGR1 mRNA levels from TCGA did not show any difference in survival between the two groups. (C) Patients with a high EGR3 nuclear fraction were borderline significant of having a poor prognosis compared to patients with a low EGR3 fraction. (D) EGR3 mRNA levels from TCGA showed the same trend as EGR3 protein levels. (E) MGMT-gene promoter methylated patients with a high EGR3 fraction lived significantly shorter than patients with a low EGR3 fraction. (F) The same trend was found in EGR3 mRNA data from TCGA, although results were non-significant. G) When sub-stratifying patients from the EGR1 high group by EGR3 expression, the group with high EGR3 expression had significantly shorter survival compared to patients with low EGR3 expression. H) Sub-stratification of patients from the EGR1 low group by EGR3 expression did not result in survival differences between the two groups. HR = Hazard ratio.